A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors

被引：16

作者：

Burris, Howard A.

Gordon, Michael S.

Hellmann, Matthew David

LoRusso, Patricia

Emens, Leisha A.

Hodi, F. Stephen

Lieu, Christopher Hanyoung

Infante, Jeffrey R.

Tsai, Frank Yung-Chin

Eder, Joseph Paul

Cleary, James M.

Jelovac, Danijela

Tsuhako, Amy L.

Mueller, Lars

Lin, Ray

Morrissey, Kari

Mahrus, Sami

Morley, Roland

Pirzkall, Andrea

Davis, Sarah Lindsey

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Virginia G Piper Canc Ctr, HonorHlth Res Inst, Pinnacle Oncol Hematol, Clin Trials Program, Scottsdale, AZ USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Karmanos Canc Inst, Detroit, MI USA

[5] Johns Hopkins Univ, Baltimore, MD USA

[6] Dana Farber Canc Inst, Boston, MA 02115 USA

[7] Univ Colorado, Denver, CO 80202 USA

[8] Tennessee Oncol PLLC, Nashville, TN USA

[9] Mem Sloan Kettering Canc Ctr, Port Washington, NY USA

[10] Yale Canc Ctr, New Haven, CT USA

[11] Johns Hopkins Univ, Baltimore, MD USA

[12] Genentech Inc, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

[13] Univ Colorado, Anschutz Med Campus, Aurora, CO USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

105

引用

页数：6